|
TMEM39A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.0547118733939E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.54871728961371E-15 |
| Normal-vs-Stage3 |
1.6251444634463E-12 |
| Normal-vs-Stage4 |
1.62536650805123E-12 |
| Stage1-vs-Stage2 |
1.480040E-02 |
| Stage1-vs-Stage3 |
1.578410E-02 |
| Stage1-vs-Stage4 |
1.612290E-02 |
| Stage2-vs-Stage3 |
5.349800E-01 |
| Stage2-vs-Stage4 |
9.127400E-01 |
| Stage3-vs-Stage4 |
5.954400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.0769163338864E-14 |
| Normal-vs-AfricanAmerican |
2.4607999999926E-06 |
| Normal-vs-Asian |
1.54249946149321E-11 |
| Caucasian-vs-AfricanAmerican |
2.791200E-01 |
| Caucasian-vs-Asian |
7.076000E-01 |
| AfricanAmerican-vs-Asian |
5.206200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
4.954200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.92210700081341E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(81-100Yrs) |
7.610000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.825500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.556670E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.483400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.014200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.526000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.025200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.438670E-03 |
| Classical-VS-Follicular |
1.468200E-02 |
| Classical-VS-Other |
2.664800E-01 |
| Classical-VS-Normal |
3.4768854462186E-12 |
| Tall-VS-Follicular |
3.140600E-01 |
| Tall-VS-Other |
8.073000E-01 |
| Tall-VS-Normal |
3.66373598126302E-15 |
| Follicular-VS-Other |
8.166600E-01 |
| Follicular-VS-Normal |
1.62481139653892E-12 |
| Other-VS-Normal |
1.381620E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
8.03801469828613E-14 |
| N0-vs-N1 |
7.502600E-01 |
|
|
